As of Wednesday close, Spero Therapeutics Inc.’s (NASDAQ:SPRO) stock was down -$0.02, moving down -1.03 percent to $1.93. The average number of shares traded per day over the past five days has been 497,220 shares. 5 times new highs have been achieved over the past 5 days, with a $0.0700 gain in that time frame. In the last twenty days, the average volume was 851,355, while in the previous 50 days, it was 7,179,104.
Since last month, SPRO stock retreated -0.52%. Shares of the company fell to $1.8000 on 11/16/22, the lowest level in the past month. A 52-week high of $16.30 was reached on 01/03/22 after having rallying from a 52-week low of $0.68. Since the beginning of this year, SPRO’s stock price has dropped by -87.95% or -$14.0800, and marked a new high 1 time. However, the stock has declined by -88.16% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
SPRO stock investors should be aware that Spero Therapeutics Inc. (SPRO) stock had its last reported insider trading activity 63 days ago on Sep 22. Aquilo Capital Management, LLC, the 10% Owner of the company, disposed of 1,901,796 shares for $2.25 on Sep 22. It resulted in a $4,279,612 divestment by the insider. Shukla Sath sold 6,017 shares at an average price of $0.89 on Aug 29. The insider now owns 56,064 shares following the transaction. On Apr 26, 10% Owner Aquilo Capital Management, LLC bought 39,727 shares at $5.24 apiece. The transaction was valued at $207,971.
The stock’s beta is 0.77. Besides these, the trailing price-to-sales (P/S) ratio of 11.29, the price-to-book (PB) ratio of 2.12.
The latest dividend of $0.0150 per share was paid out, remained unchanged from last year’s $0.0150.
In the three months ended September 29, Spero Therapeutics Inc.’s quick ratio stood at 3.30, while its current ratio was 3.30, showing that the company is able to pay off its debt. Based on annual data, SPRO earned $106.23 million in gross profit and brought in $18.26 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -64.40%. Return on equity (ROE) for the past 12 months was -186.90%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SPRO’s revenue fell -52.24% to $1.99 million during the quarter, while net income inched up to $2.01 million. While analysts expected Spero Therapeutics Inc. to report -$0.3 quarterly earnings, the actual figure was -$0.33 per share. During the quarter, the company generated -$11.58 million in EBITDA. The liabilities of Spero Therapeutics Inc. were 31.99 million at the end of its most recent quarter ended September 29, and its total debt was $6.9 million. The value of shareholders’ equity is $51.78 million.
This quick technical analysis looks at Spero Therapeutics Inc.’s (SPRO) price momentum. With a historical volatility rate of 50.90%, the RSI 9-day stood at 52.35% on 23 November.
With respect to its five-day moving average, the current Spero Therapeutics Inc. price is up by +3.76% percent or $0.0700. At present, SPRO shares trade -3.50% below its 20-day simple moving average and +147.40% percent above its 100-day simple moving average. However, the stock is currently trading approximately +108.85% above its SMA50 and -81.08% below its SMA200.
Stochastic coefficient K was 32.85% and Stochastic coefficient D was 26.09%, while ATR was 0.1112. Given the Stochastic reading of 37.68% for the 14-day period, the RSI (14) reading has been calculated as 53.06%.
Evercore ISI upgraded its rating on Spero Therapeutics Inc. (NASDAQ: SPRO) to an Outperform in a note to investors on September 23, 2022. The analysts firm previously had an In-line rating on the stock.Spero Therapeutics Inc. (SPRO) has been rated Overweight by analysts. According to 0 brokerage firms, SPRO is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Spero Therapeutics Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $5.00 – $8.00. Based on these forecasts, analysts predict Spero Therapeutics Inc. (SPRO) will achieve an average price target of $6.33.